491 related articles for article (PubMed ID: 22076431)
41. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
42. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome.
Kurosu N; Sugiura H; Iwasaki C; Asamiya Y; Kojima C; Moriyama T; Itabashi M; Tsukada M; Takei T; Ogawa T; Yoshida T; Uchida K; Tsuchiya K; Nitta K
Intern Med; 2009; 48(21):1901-4. PubMed ID: 19881243
[TBL] [Abstract][Full Text] [Related]
43. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
[TBL] [Abstract][Full Text] [Related]
44. Levamisole treatment in steroid sensitive nephrotic syndrome.
Alshaya HO; Kari JA
Saudi Med J; 2002 Sep; 23(9):1101-4. PubMed ID: 12370722
[TBL] [Abstract][Full Text] [Related]
45. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
Rodríguez-Ferrero M; Ampuero J; Anaya F
Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
[TBL] [Abstract][Full Text] [Related]
46. Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.
Stein GY; Blickstein D; Orlin J; Sarig G; Inbal A
Isr Med Assoc J; 2011 Jul; 13(7):398-401. PubMed ID: 21838180
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome.
Nakagawa T; Shiratori A; Kawaba Y; Kanda K; Tanaka R
Pediatr Int; 2016 Oct; 58(10):1003-1008. PubMed ID: 26865241
[TBL] [Abstract][Full Text] [Related]
48. [The long-term efficacy and safety of rituximab combined with cyclophosphamide in treatment of seven patients with refractory and recurrent autoimmune hemolytic anemia].
Liu H; Xing LM; Wang HQ; Wu YH; Qu W; Liang Y; Wang GJ; Song J; Wang XM; Guan J; Li LJ; Fu R; Shao ZH
Zhonghua Nei Ke Za Zhi; 2012 Jun; 51(6):456-9. PubMed ID: 22943757
[TBL] [Abstract][Full Text] [Related]
49. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children.
Donia AF; Gazareen SH; Ahmed HA; Moustafa FE; Shoeib AA; Ismail AM; Khamis S; Sobh MA
Nephrol Dial Transplant; 2003 Oct; 18(10):2054-8. PubMed ID: 13679480
[TBL] [Abstract][Full Text] [Related]
50. Long-term outcome of the difficult nephrotic syndrome in children.
Al Salloum AA; Muthanna A; Bassrawi R; Al Shehab AA; Al Ibrahim A; Islam MZ; Al Hasan K
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):965-72. PubMed ID: 22982908
[TBL] [Abstract][Full Text] [Related]
51. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
53. Difficult-to-treat nephrotic syndrome: management and outcome.
Sumboonnanonda A; Chongchate N; Suntornpoch V; Pattaragarn A; Supavekin S
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S142-8. PubMed ID: 16856434
[TBL] [Abstract][Full Text] [Related]
54. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children.
Hamed RM
J Nephrol; 1997; 10(5):266-70. PubMed ID: 9364319
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
[TBL] [Abstract][Full Text] [Related]
56. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.
Sinha MD; MacLeod R; Rigby E; Clark AG
Nephrol Dial Transplant; 2006 Jul; 21(7):1848-54. PubMed ID: 16311257
[TBL] [Abstract][Full Text] [Related]
57. Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab.
Delbue S; Ferraresso M; Elia F; Belingheri M; Carloni C; Signorini L; Carluccio S; Dallari S; Ghio L; Ferrante P
J Med Virol; 2012 Sep; 84(9):1464-70. PubMed ID: 22825826
[TBL] [Abstract][Full Text] [Related]
58. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
59. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis.
Mahmoud I; Basuni F; Sabry A; El-Husseini A; Hassan N; Ahmad NS; Elbaz M; Moustafa F; Sobh M
Nephrol Dial Transplant; 2005 Apr; 20(4):735-42. PubMed ID: 15772265
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Chan EY; Yu ELM; Angeletti A; Arslan Z; Basu B; Boyer O; Chan CY; Colucci M; Dorval G; Dossier C; Drovandi S; Ghiggeri GM; Gipson DS; Hamada R; Hogan J; Ishikura K; Kamei K; Kemper MJ; Ma AL; Parekh RS; Radhakrishnan S; Saini P; Shen Q; Sinha R; Subun C; Teo S; Vivarelli M; Webb H; Xu H; Yap HK; Tullus K
J Am Soc Nephrol; 2022 Jun; 33(6):1193-1207. PubMed ID: 35354600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
